Last reviewed · How we verify
Paclitaxel, Carboplatin, Pembrolizumab
Paclitaxel, Carboplatin, Pembrolizumab is a Small molecule drug developed by Samsung Medical Center. It is currently in Phase 2 development. Also known as: Anzatax, Preizer carboplatin, keytruda.
At a glance
| Generic name | Paclitaxel, Carboplatin, Pembrolizumab |
|---|---|
| Also known as | Anzatax, Preizer carboplatin, keytruda |
| Sponsor | Samsung Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer (PHASE3)
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (PHASE1)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paclitaxel, Carboplatin, Pembrolizumab CI brief — competitive landscape report
- Paclitaxel, Carboplatin, Pembrolizumab updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI
Frequently asked questions about Paclitaxel, Carboplatin, Pembrolizumab
What is Paclitaxel, Carboplatin, Pembrolizumab?
Paclitaxel, Carboplatin, Pembrolizumab is a Small molecule drug developed by Samsung Medical Center.
Who makes Paclitaxel, Carboplatin, Pembrolizumab?
Paclitaxel, Carboplatin, Pembrolizumab is developed by Samsung Medical Center (see full Samsung Medical Center pipeline at /company/samsung-medical-center).
Is Paclitaxel, Carboplatin, Pembrolizumab also known as anything else?
Paclitaxel, Carboplatin, Pembrolizumab is also known as Anzatax, Preizer carboplatin, keytruda.
What development phase is Paclitaxel, Carboplatin, Pembrolizumab in?
Paclitaxel, Carboplatin, Pembrolizumab is in Phase 2.
Related
- Manufacturer: Samsung Medical Center — full pipeline
- Also known as: Anzatax, Preizer carboplatin, keytruda
- Compare: Paclitaxel, Carboplatin, Pembrolizumab vs similar drugs
- Pricing: Paclitaxel, Carboplatin, Pembrolizumab cost, discount & access